Miao He

Miao He, PhD MBA, is a Senior Associate at Hadean Ventures since August 2021, where the focus is on life science investments with approximately EUR 250 million in assets under management. Miao serves as a Board Observer for Neuro Event Labs Oy and previously for Cardior Pharmaceuticals, which is set for acquisition by Novo Nordisk for up to EUR 1.025 billion. Prior roles include Associate at Luminous Ventures, MBA Consultant for Ori Biotech, Summer Associate at OurCrowd, and Project Consultant at Cancer Research UK. Miao's career in bioinformatics began with positions at Illumina and culminated as a Postdoctoral Researcher at the Wellcome Trust Sanger Institute. Educational credentials include a PhD in Molecular Biology from the University of Cambridge, an MBA from London Business School, and a BSc in Biological Sciences from Fudan University.